Astragaloside IV Alleviates Cisplatin Chemotherapy‐Induced Nephrotoxicity via Modulation of Nrf2/HO‐1/NF‐κB Pathway and Reversal of EMT Process
Journal of Biochemical and Molecular Toxicology · 2025
DOI: 10.1002/jbt.70565 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Biochemical and Molecular Toxicology, 2025. Verfasst von Xiaoyun Ding und 5 weiteren Autor:innen. Beteiligte Einrichtung: Oncology Hospital, General Hospital of Ningxia Medical University, Yinchuan, China. Hauptthemen laut MEDLINE: Cisplatin, Saponins, NF-E2-Related Factor 2, Triterpenes. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 40 Literaturangaben. Gefördert von: This study was funded by the Natural Science Foundation of Ningxia (Grant Nos. 2021AAC03144 and 2023AAC03245)..
Themen: Onkologische Pflege
Abstract (Originalsprache)
High incidence of nephrotoxicity poses a significant hurdle to the clinical utility of cisplatin (CDDP), which profoundly impacts the efficacy of chemotherapy. Astragaloside IV (AS‐IV) is a characteristic saponin component of Astragalus membranaceus , known for its antioxidant and anti‐inflammatory properties. However, the precise role of AS‐IV in the context of CDDP chemotherapy remains elusive. Herein, we unveil AS‐IV's capability to alleviate CDDP‐induced nephrotoxicity in Lewis lung carcinoma mice and renal tubular epithelial cells (RTECs). This is achieved by upregulating antioxidant enzymes, activating Nrf2/HO‐1 pathway, while concurrently suppressing release of pro‐inflammatory cytokines and inhibiting p‐NF‐κB(p65) expression. Furthermore, our research reveals the anti‐fibrosis ability of AS‐IV on RTECs induced by inflammatory mediators TNF‐α and TGF‐β1 through reversal of the epithelial‐mesenchymal transformation (EMT) process. These findings not only suggest the viable potential of AS‐IV in combination with CDDP to alleviate nephrotoxicity, but also underscore its medicinal promise in enhancing chemotherapy effectiveness.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Oncology Hospital, General Hospital of Ningxia Medical University, Yinchuan, China.
- School of Pharmacy, Ningxia Medical University, Yinchuan, China.
ORCID-Profile: Jing Wang
Förderung
- This study was funded by the Natural Science Foundation of Ningxia (Grant Nos. 2021AAC03144 and 2023AAC03245).
Zitieren
APA
Ding, X., Han, X., Zhang, Y., Zhang, Y., Li, F., & Wang, J. (2025). Astragaloside IV Alleviates Cisplatin Chemotherapy‐Induced Nephrotoxicity via Modulation of Nrf2/HO‐1/NF‐κB Pathway and Reversal of EMT Process. Journal of Biochemical and Molecular Toxicology. https://doi.org/10.1002/jbt.70565
Vancouver
Ding X, Han X, Zhang Y, Zhang Y, Li F, Wang J. Astragaloside IV Alleviates Cisplatin Chemotherapy‐Induced Nephrotoxicity via Modulation of Nrf2/HO‐1/NF‐κB Pathway and Reversal of EMT Process. Journal of Biochemical and Molecular Toxicology. 2025. doi:10.1002/jbt.70565
BibTeX
@article{Ding2025,
author = {Ding, Xiaoyun and Han, Xue and Zhang, Yue and Zhang, Yan and Li, Fengmei and Wang, Jing},
title = {Astragaloside IV Alleviates Cisplatin Chemotherapy‐Induced Nephrotoxicity via Modulation of Nrf2/HO‐1/NF‐κB Pathway and Reversal of EMT Process},
journal = {Journal of Biochemical and Molecular Toxicology},
year = {2025},
doi = {10.1002/jbt.70565}
}
EUVIMED